Autolus Therapeutics Hits New 52-Week Low - What's Next?

Autolus Therapeutics plc (NASDAQ:AUTL) has recently seen its share price fall to a new 52-week low. On Monday, the stock traded as low as $1.86 before closing at $1.88. During this trading session, approximately 258,277 shares changed hands. In comparison, the previous closing price was $1.95.

Analyst Ratings

Several research analysts have shared their thoughts on Autolus Therapeutics. Redburn Atlantic upgraded the stock from a "neutral" to a "buy" rating, setting a target price of $13.00. Similarly, Needham & Company LLC reaffirmed its "buy" rating and set a price objective of $10.00. Additionally, The Goldman Sachs Group raised their rating from "neutral" to "buy" and increased the target price from $7.00 to $7.60. Currently, five analysts have issued buy ratings for the stock. According to MarketBeat.com, Autolus Therapeutics has an average rating of "Buy" and a consensus target price of $10.40.

Current Trading Status

The stock has seen a decline of 2.3%. Its 50-day moving average price stands at $2.23, while the 200-day moving average is at $3.18. The company holds a market capitalization of approximately $506.90 million, with a price-to-earnings ratio of -1.57 and a beta of 2.02.

Institutional Activity

In terms of institutional interest, various hedge funds have made adjustments to their positions in Autolus Therapeutics. For example, China Universal Asset Management Co. Ltd. increased its stake by 63.8% during the third quarter. This company now owns 38,393 shares valued at around $139,000. At the same time, Privium Fund Management B.V. raised its holdings by 15.6% and owns 185,639 shares valued at approximately $674,000. Another significant move was made by HealthInvest Partners AB, which grew its position by 95.6%, now holding 442,423 shares worth around $1,606,000. Overall, 72.83% of the shares are held by institutional investors and hedge funds.

Company Overview

Autolus Therapeutics is a clinical-stage biopharmaceutical company focused on developing T cell therapies aimed at treating cancer and autoimmune diseases. The company’s portfolio includes several clinical-stage programs, such as obecabtagene autoleucel (AUTO1), which targets CD19 and is in a Phase 1b/2 trial for adult acute lymphoblastic leukemia (ALL). Other therapies in development include AUTO1/22, AUTO4, AUTO6NG, and AUTO8, targeting various cancer forms like neuroblastoma and multiple myeloma.

Investment Consideration

Before considering an investment in Autolus Therapeutics, it is advisable to look at other options. Current analysts have rated the stock as a "Buy," but further research indicates that there might be more promising investments. It is important for potential investors to do thorough research and consider a setup of stocks recommended by the top-performing analysts.

stocks, analysis, investing